Susquehanna International Group’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
Other funds holding AVIR
BCM
TCM
VCM
BCLSI
Susquehanna International Group's AVIR Position: Q1 2026 in Review
Susquehanna International Group increased its Atea Pharmaceuticals (AVIR) stake by 377% in Q1 2026, buying an estimated $297K and bringing the position to 81,835 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #9987.
Susquehanna International Group first reported a position in AVIR in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.75M in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.
- Susquehanna International Group held 81,835 shares of Atea Pharmaceuticals worth $440K as of Q1 2026.
- Susquehanna International Group bought 64,679 Atea Pharmaceuticals shares in Q1 2026, an estimated $297K.
- Atea Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9987 holding.
- Susquehanna International Group first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
- Susquehanna International Group's Atea Pharmaceuticals position peaked at $2.75M in Q3 2021.
- 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.